The latest news from ASH 2024 focused on multiple myeloma (MM) including abstracts, features, and helpful conference information.
Monoclonal antibody delayed progression to MM, improved PFS, ORR, and OS, and was well tolerated in high-risk SMM, supporting early intervention over monitoring.
This year’s ASH was exceptionally busy, with overlapping sessions, including three back-to-back myeloma talks. Key studies showcased practice-changing findings.
iMMagine-1 phase 2 trial shows 97% response, 62% complete response in relapsed/refractory myeloma, with strong safety and promising 2026 launch.
A recent study evaluated the impact of circulating plasma cells in patients with primary multiple myeloma on bortezomib-containing induction therapy.
Addition of elotuzumab to standard therapy in transplant-eligible patients with MM did not improve PFS or OS in the long-term follow-up of the GMMG-HD6 trial.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
